herobanner-homepage

Imagine Everyday Moments With Symptom Relief

You and your doctor can work together to find a medicine that may help improve your symptoms. XELJANZ is a pill approved to treat adults when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or cannot be tolerated with:

XELJANZ is approved to treat patients ages 2 and older when TNF blockers did not work well or could not be tolerated with:

XELJANZ is a pill, not an injection or infusion
pill in hand

10 Years in RA

XELJANZ has been prescribed for more than 10 years, since initial approval in 2012, for adults with moderate to severe rheumatoid arthritis.* XELJANZ was approved for use in adults with active psoriatic arthritis* in 2017, adults with moderate to severe ulcerative colitis* in 2018, and adults with active ankylosing spondylitis in 2021.

In 2020, XELJANZ was approved for use in patients ages 2 and older with active polyarticular course juvenile idiopathic arthritis.*

*Indication revised to use in patients who have not responded or cannot tolerate one or more TNF blockers.

https://main--xeljanzcomxeljanz--pfizer.hlx.page/fragments/first-approved Metadata
people taking photograph

Getting Started With XELJANZ

Molecule graphic

How XELJANZ Works

XELJANZ is a Janus kinase (JAK) inhibitor that helps regulate an overactive immune system. It helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation.

Discover Support Resources

Take an active role in your treatment with tools and support resources—delivered directly to you. We’ll start by sending a Welcome Kit in the mail and will follow up with occasional emails containing timely information and lifestyle tips.

Sign Up Now

XELJANZ (tofacitinib) resource support brochures